Longer course of esketamine nasal spray benefits initial treatment nonresponders
The Brown University Psychopharmacology Update November 1, 2021 DOI: 10.1002/pu.30792 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Post hoc analysis of two Phase 3 studies Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression who did not respond within the first week of treatment |
| Interventions | Esketamine nasal spray oral antidepressant |
| Duration | 4 weeks |
| Topics | Esketamine |
| Key points | Extending adjunctive esketamine nasal spray treatment over 4 weeks showed benefit in patients with treatment-resistant depression who did not respond within the first week. The researchers suggest that a full 4-week induction of esketamine with an oral antidepressant may optimize treatment outcomes. |
Abstract
Extending adjunctive treatment with esketamine nasal spray over 4 weeks showed benefit in a group of patients with treatment‐resistant depression who did not respond within the first week of treatment, a post hoc analysis of two Phase 3 studies has found. The results suggest that a full 4‐week induction of esketamine with an oral antidepressant may optimize treatment outcomes, the researchers stated. Results of the analysis were published online July 20, 2021, in the Journal of Clinical Psychiatry.
Comparable studies
Other observational and cohort studies on esketamine, most cited first.